A Spanish pharma compounder re-rates—or de-rates—on SIFI integration and Akantior’s FDA outcome.
Overview
Faes Farma (FAE.MC) is a 90+ year Spanish integrated pharma and healthcare group with two main engines: a dominant Pharmaceuticals division (~87.5% of revenue historically) and an Animal Nutrition & Health unit (FARM Faes). The pharma business is anchored by three key molecules—Bilastine (allergy/urticaria), Calcifediol (vitamin D derivative for bone health), and Mesalazine (IBD)—sold via direct prescription networks (Iberia/LATAM) and out-licensing agreements that generate high-margin royalties. Although Bilastine’s core EU patent expired in 2022, the franchise remains resilient via geographic expansion and lifecycle innovation (pediatric and alternative delivery formats). Strategically, the company is pivoting toward ophthalmology, crystallized by two 2025 acquisitions: Edol in Portugal and SIFI in Italy, bringing ophthalmology to ~20% of pro-forma revenue while adding specialized manufacturing (BFS/MDPF) and a rare-disease pipeline asset, Akantior. FARM Faes is scaling rapidly after commissioning a major new plant in Huesca, contributing strong growth. Overall, Faes Farma combines a cash-generative base business with an integration-led transformation that could drive a valuation re-rating if execution and Akantior’s regulatory path play out.